Angiogenesis Inhibitors for Head and Neck Squamous Cell Carcinoma Treatment : Is There Still Hope?

Show full item record



Permalink

http://hdl.handle.net/10138/333884

Citation

Hyytiäinen , A , Wahbi , W , Väyrynen , O , Saarilahti , K , Karihtala , P , Salo , T & Al-Samadi , A 2021 , ' Angiogenesis Inhibitors for Head and Neck Squamous Cell Carcinoma Treatment : Is There Still Hope? ' , Frontiers in oncology , vol. 11 , 683570 . https://doi.org/10.3389/fonc.2021.683570

Title: Angiogenesis Inhibitors for Head and Neck Squamous Cell Carcinoma Treatment : Is There Still Hope?
Author: Hyytiäinen, Aini; Wahbi, Wafa; Väyrynen, Otto; Saarilahti, Kauko; Karihtala, Peeter; Salo, Tuula; Al-Samadi, Ahmed
Contributor: University of Helsinki, Research Programs Unit
University of Helsinki, Department of Oral and Maxillofacial Diseases
University of Helsinki, Department of Oral and Maxillofacial Diseases
University of Helsinki, HUS Comprehensive Cancer Center
University of Helsinki, Department of Oncology
University of Helsinki, HUSLAB
University of Helsinki, Department of Oral and Maxillofacial Diseases
Date: 2021-06-14
Language: eng
Number of pages: 23
Belongs to series: Frontiers in oncology
ISSN: 2234-943X
URI: http://hdl.handle.net/10138/333884
Abstract: Background Head and neck squamous cell carcinoma (HNSCC) carries poor survival outcomes despite recent progress in cancer treatment in general. Angiogenesis is crucial for tumour survival and progression. Therefore, several agents targeting the pathways that mediate angiogenesis have been developed. We conducted a systematic review to summarise the current clinical trial data examining angiogenesis inhibitors in HNSCC. Methods We carried out a literature search on three angiogenesis inhibitor categories-bevacizumab, tyrosine kinase inhibitors and endostatin-from Ovid MEDLINE, Cochrane Library, Scopus and ClinicalTrials.gov database. Results Here, we analysed 38 clinical trials, total of 1670 patients, investigating 12 angiogenesis inhibitors. All trials were in phase I or II, except one study in phase III on bevacizumab. Angiogenesis inhibitors were used as mono- and combination therapies together with radio-, chemo-, targeted- or immunotherapy. Among 12 angiogenesis inhibitors, bevacizumab was the most studied drug, included in 13 trials. Although bevacizumab appeared effective in various combinations, it associated with high toxicity levels. Endostatin and lenvatinib were well-tolerated and their anticancer effects appeared promising. Conclusions Most studies did not show benefit of angiogenesis inhibitors in HNSCC treatment. Additionally, angiogenesis inhibitors were associated with considerable toxicity. However, some results appear encouraging, suggesting that further investigations of angiogenesis inhibitors, particularly in combination therapies, for HNSCC patients are warranted. Systematic Review Registration PROSPERO (https://www.crd.york.ac.uk/prospero/), identifier CRD42020157144.
Subject: anti-angiogenesis
head and neck cancer
therapy
endostatin
bevacizumab
PHASE-II-TRIAL
ADVANCED NASOPHARYNGEAL CARCINOMA
RECOMBINANT HUMAN ENDOSTATIN
AND/OR METASTATIC HEAD
LOCALLY ADVANCED HEAD
RADIATION-THERAPY
CONCURRENT CHEMORADIATION
HEPATOCELLULAR-CARCINOMA
TARGETING ANGIOGENESIS
TUMOR ANGIOGENESIS
3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
fonc_11_683570.pdf 991.8Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record